Key result
Cardiac AAV gene therapy is an emerging platform for treating intractable cardiac disorders, with recent progress in preclinical models and clinical trials for heart failure.
Population
Patients with heart failure and preclinical animal models
Design
Review
Authors
Loading...
Leaves open AAV gene therapy for intractable heart failure; randomized human trials needed before clinical consideration.
Cardiac AAV gene therapy is an emerging platform for treating heart failure, though efficient myocardial delivery remains a significant translational obstacle.
Chamberlain et al. (2017) conducted a review in Cardiac disorders / Heart failure. Cardiac AAV gene therapy was evaluated. Cardiac AAV gene therapy is an emerging platform for treating intractable cardiac disorders, with recent progress in preclinical models and clinical trials for heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: